Additionally, tyrosine kinase inhibitors (TKIs), which target receptor tyrosine kinases involved in EMT signaling (such as Wnt β-catenin, TGF-β signaling and notch signaling), have demonstrated efficacy in cancer therapy by inhibiting growth factor-mediated EMT signaling [85,86,87]. The gene discussed is TGFB1; the disease is cancer.